View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
ABGSC Capital Goods Research ... (+3)
  • ABGSC Capital Goods Research
  • Henric Hintze
  • Karl Bokvist
ABGSC Capital Goods Research ... (+3)
  • ABGSC Capital Goods Research
  • Anders Idborg
  • Karl Bokvist
ABGSC IT Research ... (+3)
  • ABGSC IT Research
  • Daniel Thorsson
  • Simon Granath
ABGSC Retail Research ... (+3)
  • ABGSC Retail Research
  • Benjamin Wahlstedt
  • Fredrik Ivarsson
Patrik Ling
  • Patrik Ling

Swedish Orphan Biovitrum (Buy, TP: SEK365.00) - Haemophilia the highli...

Q1 sales beat our forecast by 5% and adj. EBITA outperformed by 8%. Overall, we believe the highlight in the report was the stronger haemophilia result than expected, with solid growth in Altuvoct and a smaller decline for Elocta than forecast. The weak spot was Vonjo sales, which missed our estimate by 28% and consensus by 29%, with management citing stocking issues. We reiterate our BUY and SEK365 target price.

Miika Ihamaki
  • Miika Ihamaki

Kesko (Buy, TP: EUR21.50) - Steady progress

Q1 clean EBIT missed consensus by 3% on weaker GT, but we believe its margin concerns were well addressed, and improved hypermarket sales relative to the market point to an encouraging trend. After years of weakness, BTT profitability also expanded. We have made minor estimate changes (cut 2025–2027e clean EBIT by c2–0%) and raised our target price to EUR21.5 (20.5), due to our higher conviction on improved GT market-share momentum, which serves as a valuation trigger in the investment case, in ...

ABGSC Retail Research ... (+2)
  • ABGSC Retail Research
  • Fredrik Ivarsson
ABGSC Capital Goods Research ... (+3)
  • ABGSC Capital Goods Research
  • Anders Idborg
  • Karl Bokvist
Mattias Holmberg
  • Mattias Holmberg

Epiroc (Hold, TP: SEK220.00) - Solid equipment demand

A solid Q1 report included orders and sales up 10% and 3% organically YOY, respectively, and an adj. EBIT margin of 19.9%; however, this included a 190bp FX boost, and we believe underlying margins could remain under pressure until the service mix improves. Albeit with increased uncertainty, management guided for mining demand to remain strong but construction to remain weak near-term. We have trimmed our 2025–2027e sales and adj. EBIT by 2% (FX-related) but reiterate our HOLD and SEK220 target ...

ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Alexander Krämer
  • Morten Larsen
ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Alexander Krämer
  • Morten Larsen
ABGSC Capital Goods Research ... (+3)
  • ABGSC Capital Goods Research
  • Anders Idborg
  • Karl Bokvist
ABGSC Retail Research ... (+2)
  • ABGSC Retail Research
  • Fredrik Ivarsson
ABGSC Capital Goods Research ... (+3)
  • ABGSC Capital Goods Research
  • Anders Idborg
  • Karl Bokvist
Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch